Generic placeholder image

Current Medicinal Chemistry

Author(s): Ahmet Kor*, Kevser Orhan, Yüksel Maraş, Esra Fırat Oğuz, Mehtap Kalçık Unan, Gamze Dilek, Şükran Erten and Kemal Nas

DOI: 10.2174/0109298673295359240422115759

DownloadDownload PDF Flyer Cite As
Does Eta Protein Differentiate Rheumatoid Arthritis from Psoriatic Arthritis?

Page: [6510 - 6520] Pages: 11

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Aim: The clinical symptoms and laboratory markers of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) can be very similar, so making a differential diagnosis between these two diseases is often difficult. Serological parameters to be used in differential diagnosis can guide the clinician. This study aimed to investigate the usability of 14-3-3η (eta) protein as a biomarker in the differential diagnosis of PsA and RA, and the relationships between eta protein and disease activity scores and joint erosions in PsA and RA.

Methods: 54 PsA patients, 53 RA patients, and 56 healthy individuals were included in this study. The ELISA (Enzyme-Linked ImunoSorbent Assay) kit was used as a quantitative sandwich enzyme immunoassay technique to detect human eta protein levels. Receiver- operating Characteristic (ROC) curves analysis was used to determine the sensitivity and specificity of the eta protein.

Results: Eta protein levels were found to be significantly higher in the RA group than in the PsA [B: -0.341, OR (95% CI): 0.711 (0.556-0.909), p: 0.007] and control [B: -0.225, OR (95% CI): 0.798 (0.641-0.995), p: 0.045] groups. Eta protein median values were significantly higher in patients with joint erosion than in those without [β= 0.151, OR (95% CI): 1.163 (1.003-1.349), p: 0.046].

Conclusion: Eta protein levels are higher in the serum of RA patients than PsA and are associated with joint erosion. Eta protein may be a potential biomarker in the differential diagnosis of RA and PsA. It may represent a possible therapeutic step in the pathophysiological pathways in the development of joint erosion.

Keywords: 14-3-3η protein, rheumatoid arthritis, psoriatic arthritis, joint erosion, disease activity, visual analog scale.

[1]
Ritchlin, C.T.; Colbert, R.A.; Gladman, D.D. Psoriatic Arthritis. N. Engl. J. Med., 2017, 376(10), 957-970.
[http://dx.doi.org/10.1056/NEJMra1505557] [PMID: 28273019]
[2]
Smolen, J.S.; Landewé, R.; Bijlsma, J.; Burmester, G.; Chatzidionysiou, K.; Dougados, M.; Nam, J.; Ramiro, S.; Voshaar, M.; van Vollenhoven, R.; Aletaha, D.; Aringer, M.; Boers, M.; Buckley, C.D.; Buttgereit, F.; Bykerk, V.; Cardiel, M.; Combe, B.; Cutolo, M.; van Eijk-Hustings, Y.; Emery, P.; Finckh, A.; Gabay, C.; Gomez-Reino, J.; Gossec, L.; Gottenberg, J.E.; Hazes, J.M.W.; Huizinga, T.; Jani, M.; Karateev, D.; Kouloumas, M.; Kvien, T.; Li, Z.; Mariette, X.; McInnes, I.; Mysler, E.; Nash, P.; Pavelka, K.; Poór, G.; Richez, C.; van Riel, P.; Rubbert-Roth, A.; Saag, K.; da Silva, J.; Stamm, T.; Takeuchi, T.; Westhovens, R.; de Wit, M.; van der Heijde, D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis., 2017, 76(6), 960-977.
[http://dx.doi.org/10.1136/annrheumdis-2016-210715] [PMID: 28264816]
[3]
Knani, I.; Bouzidi, H.; Zrour, S.; Bergaoui, N.; Hammami, M.; Kerkeni, M. Increased serum concentrations of N ɛ -carboxymethyllysine are related to the presence and the severity of rheumatoid arthritis. Ann. Clin. Biochem., 2018, 55(4), 430-436.
[http://dx.doi.org/10.1177/0004563217733500] [PMID: 28882063]
[4]
Van Hoovels, L.; Vander Cruyssen, B.; Sieghart, D.; Bonroy, C.; Nagy, E.; Pullerits, R.; Čučnik, S.; Dahle, C.; Heijnen, I.; Bernasconi, L.; Benkhadra, F.; Bogaert, L.; Van Den Bremt, S.; Van Liedekerke, A.; Vanheule, G.; Robbrecht, J.; Studholme, L.; Wirth, C.; Müller, R.; Kyburz, D.; Sjöwall, C.; Kastbom, A.; Ješe, R.; Jovancevic, B.; Kiss, E.; Jacques, P.; Aletaha, D.; Steiner, G.; Verschueren, P.; Bossuyt, X. IgA rheumatoid factor in rheumatoid arthritis. Clin. Chem. Lab. Med., 2022, 60(10), 1617-1626.
[http://dx.doi.org/10.1515/cclm-2022-0244] [PMID: 35790193]
[5]
Smolen, J.S. Rheumatoid arthritis Primer behind the scenes. Nat. Rev. Dis. Primers, 2020, 6(1), 32.
[http://dx.doi.org/10.1038/s41572-020-0168-y] [PMID: 32327647]
[6]
Smolen, J.S.; Landewé, R.B.M.; Bijlsma, J.W.J.; Burmester, G.R.; Dougados, M.; Kerschbaumer, A.; McInnes, I.B.; Sepriano, A.; van Vollenhoven, R.F.; de Wit, M.; Aletaha, D.; Aringer, M.; Askling, J.; Balsa, A.; Boers, M.; den Broeder, A.A.; Buch, M.H.; Buttgereit, F.; Caporali, R.; Cardiel, M.H.; De Cock, D.; Codreanu, C.; Cutolo, M.; Edwards, C.J.; van Eijk-Hustings, Y.; Emery, P.; Finckh, A.; Gossec, L.; Gottenberg, J.E.; Hetland, M.L.; Huizinga, T.W.J.; Koloumas, M.; Li, Z.; Mariette, X.; Müller-Ladner, U.; Mysler, E.F.; da Silva, J.A.P.; Poór, G.; Pope, J.E.; Rubbert-Roth, A.; Ruyssen-Witrand, A.; Saag, K.G.; Strangfeld, A.; Takeuchi, T.; Voshaar, M.; Westhovens, R.; van der Heijde, D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis., 2020, 79(6), 685-699.
[http://dx.doi.org/10.1136/annrheumdis-2019-216655] [PMID: 31969328]
[7]
Popescu, C.; Zofotă, S.; Bojincă, V.; Ionescu, R. Anti- cyclic citrullinated peptide antibodies in psoriatic arthritis--cross-sectional study and literature review. J. Med. Life, 2013, 6(4), 376-382.
[PMID: 24701255]
[8]
Bizzaro, N. Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis. Clin. Chem. Lab. Med., 2007, 45(2), 150-157.
[http://dx.doi.org/10.1515/CCLM.2007.027] [PMID: 17311500]
[9]
Burmester, G.R.; Pope, J.E. Novel treatment strategies in rheumatoid arthritis. Lancet, 2017, 389(10086), 2338-2348.
[http://dx.doi.org/10.1016/S0140-6736(17)31491-5] [PMID: 28612748]
[10]
Gossec, L.; Smolen, J.S.; Ramiro, S.; de Wit, M.; Cutolo, M.; Dougados, M.; Emery, P.; Landewé, R.; Oliver, S.; Aletaha, D.; Betteridge, N.; Braun, J.; Burmester, G.; Cañete, J.D.; Damjanov, N.; FitzGerald, O.; Haglund, E.; Helliwell, P.; Kvien, T.K.; Lories, R.; Luger, T.; Maccarone, M.; Marzo-Ortega, H.; McGonagle, D.; McInnes, I.B.; Olivieri, I.; Pavelka, K.; Schett, G.; Sieper, J.; van den Bosch, F.; Veale, D.J.; Wollenhaupt, J.; Zink, A.; van der Heijde, D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann. Rheum. Dis., 2016, 75(3), 499-510.
[http://dx.doi.org/10.1136/annrheumdis-2015-208337] [PMID: 26644232]
[11]
Ritchlin, C.T.; Krueger, J.G. New therapies for psoriasis and psoriatic arthritis. Curr. Opin. Rheumatol., 2016, 28(3), 204-210.
[http://dx.doi.org/10.1097/BOR.0000000000000274] [PMID: 27022911]
[12]
Cau, Y.; Valensin, D.; Mori, M.; Draghi, S.; Botta, M. Structure, function, involvement in diseases and targeting of 14-3-3 proteins: an update. Curr. Med. Chem., 2018, 25(1), 5-21.
[http://dx.doi.org/10.2174/0929867324666170426095015] [PMID: 28462702]
[13]
Maksymowych, W.P.; van der Heijde, D.; Allaart, C.F.; Landewé, R.; Boire, G.; Tak, P.P.; Gui, Y.; Ghahary, A.; Kilani, R.; Marotta, A. 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res. Ther., 2014, 16(2), R99.
[http://dx.doi.org/10.1186/ar4547] [PMID: 24751211]
[14]
Doğan, İ.; Kor, A.; Güven, S.C.; Fırat Oğuz, E.; Başer, S.; Atalar, E.; Maraş, Y.; Erel, Ö.; Erten, Ş. 14–3-3 η ETA protein as a potential marker of joint damage in gout. Clin. Biochem., 2023, 118, 110611.
[http://dx.doi.org/10.1016/j.clinbiochem.2023.110611] [PMID: 37429510]
[15]
Wang, D.; Cui, Y.; Lei, H.; Cao, D.; Tang, G.; Huang, H.; Yuan, T.; Rao, L.; Mo, B. Diagnostic accuracy of 14-3-3 η protein in rheumatoid arthritis: A meta-analysis. Int. J. Rheum. Dis., 2020, 23(11), 1443-1451.
[http://dx.doi.org/10.1111/1756-185X.13921] [PMID: 32909672]
[16]
Hammam, N.; Salah, S.; Kholef, E.F.; Moussa, E.M.; Marotta, A. 14-3-3η Protein in serum and synovial fluid correlates with radiographic damage and progression in a longitudinal evaluation of patients with established rheumatoid arthritis. Mod. Rheumatol., 2020, 30(4), 664-670.
[http://dx.doi.org/10.1080/14397595.2019.1637575] [PMID: 31242798]
[17]
Hu, T.; Liu, Y.; Tan, L.; Huang, J.; Yu, J.; Wu, Y.; Pei, Z.; Zhang, X.; Li, J.; Song, L.; Dai, W.; Xiang, Y. Value of serum collagen triple helix repeat containing-1(CTHRC1) and 14-3-3η protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis. Br. J. Biomed. Sci., 2021, 78(2), 67-71.
[http://dx.doi.org/10.1080/09674845.2020.1810400] [PMID: 32813981]
[18]
Kilani, R.T.; Maksymowych, W.P.; Aitken, A.; Boire, G.; St-Pierre, Y.; Li, Y.; Ghahary, A. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J. Rheumatol., 2007, 34(8), 1650-1657.
[PMID: 17611984]
[19]
Wei, J.C.C.; Leong, P.Y.; Liu, G.Y. Chaperone/scaffolding/adaptor protein 14-3-3η (eta): A diagnostic marker of rheumatoid arthritis. Int. J. Rheum. Dis., 2020, 23(11), 1439-1442.
[http://dx.doi.org/10.1111/1756-185X.14004] [PMID: 33225576]
[20]
Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O., III; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; Combe, B.; Costenbader, K.H.; Dougados, M.; Emery, P.; Ferraccioli, G.; Hazes, J.M.W.; Hobbs, K.; Huizinga, T.W.J.; Kavanaugh, A.; Kay, J.; Kvien, T.K.; Laing, T.; Mease, P.; Ménard, H.A.; Moreland, L.W.; Naden, R.L.; Pincus, T.; Smolen, J.S.; Stanislawska-Biernat, E.; Symmons, D.; Tak, P.P.; Upchurch, K.S.; Vencovský, J.; Wolfe, F.; Hawker, G. 2010 rheumatoid arthritis classification criteria: An American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum., 2010, 62(9), 2569-2581.
[http://dx.doi.org/10.1002/art.27584] [PMID: 20872595]
[21]
Taylor, W.; Gladman, D.; Helliwell, P.; Marchesoni, A.; Mease, P.; Mielants, H.; Group, C.S. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum., 2006, 54(8), 2665-2673.
[http://dx.doi.org/10.1002/art.21972] [PMID: 16871531]
[22]
Machado, P.M.; Raychaudhuri, S.P. Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. Best Pract. Res. Clin. Rheumatol., 2014, 28(5), 711-728.
[http://dx.doi.org/10.1016/j.berh.2014.10.004] [PMID: 25488780]
[23]
Nas, K.; Kiliç, E.; Tekeoğlu, İ.; Keskin, Y.; Çevik, R.; Sargin, B.; Acer Kasman, S.; Alkan, H.; Sahin, N.; Cengiz, G.; Cüzdan, N.; Albayrak Gezer, İ.; Keskin, D.; Mülkoglu, C.; Reşorlu, H.; Ataman, Ş.; Bal, A.; Baykul, M.; Duruöz, M.T.; Küçükakkaş, O.; Yurdakul, O.V.; Alkan Melikoğlu, M.; Ayhan, F.F.; Bodur, H.; Çaliş, M.; Çapkin, E.; Devrimsel, G.; Gök, K.; Hizmetli, S.; Kamanlı, A.; Kocabaş, H.; Kutluk, Ö.; Şen, N.; Şendur, Ö.F.; Toprak, M.; Tolu, S.; Tuncer, T. The effect of gender on disease activity and clinical characteristics in patients with axial psoriatic arthritis. Mod. Rheumatol., 2021, 31(4), 869-874.
[http://dx.doi.org/10.1080/14397595.2020.1812870] [PMID: 32820672]
[24]
Garip, Y.; Eser, F.; Bodur, H. Health-related quality of life in rheumatoid arthritis: comparison of RAQoL with other scales in terms of disease activity, severity of pain, and functional status. Rheumatol. Int., 2011, 31(6), 769-772.
[http://dx.doi.org/10.1007/s00296-009-1353-1] [PMID: 20180124]
[25]
Anderson, J.; Caplan, L.; Yazdany, J.; Robbins, M.L.; Neogi, T.; Michaud, K.; Saag, K.G.; O’dell, J.R.; Kazi, S. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res. (Hoboken), 2012, 64(5), 640-647.
[http://dx.doi.org/10.1002/acr.21649] [PMID: 22473918]
[26]
Human 14-3-3 protein eta (YWHAH) ELISA kit. Available from: https://www.cusabio.com/ELISA-Kit/Human-14-3-3-protein-etaYWHAH-ELISA-kit-112977.html#a05
[27]
Salman, E.; Çeti̇ner, S.; Boral, B.; Ki̇bar, F.; Erken, E.; Ersözlü, E.D.; Badak, S.Ö.; Bi̇li̇ci̇ Salman, R.; Sertdemi̇r, Y.; Çeti̇n Duran, A.; Yaman, A. Importance of 14-3-3 eta, anti- CarP, and anti-Sa in the diagnosis of seronegative rheumatoid arthritis. Turk. J. Med. Sci., 2019, 49(5), 1498-1502.
[http://dx.doi.org/10.3906/sag-1812-137] [PMID: 31651120]
[28]
Guan, S.Z.; Yang, Y.Q.; Bai, X.; Wang, Y.; Feng, K.Q.; Zhang, H.J.; Dong, M.; Yang, H.W.; Li, H.Q. Serum 14-3-3η could improve the diagnostic rate of rheumatoid arthritis and correlates to disease activity. Ann. Clin. Lab. Sci., 2019, 49(1), 57-62.
[PMID: 30814078]
[29]
Souto-Carneiro, M.; Tóth, L.; Behnisch, R.; Urbach, K.; Klika, K.D.; Carvalho, R.A.; Lorenz, H.M. Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis. Ann. Rheum. Dis., 2020, 79(4), 499-506.
[http://dx.doi.org/10.1136/annrheumdis-2019-216374] [PMID: 32079570]
[30]
Gong, X.; Xu, S.; Wu, Y.; Ma, C.; Qi, S.; Liu, W.; Xu, J. Elevated serum 14-3-3η protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population. Clin. Rheumatol., 2017, 36(11), 2581-2587.
[http://dx.doi.org/10.1007/s10067-017-3807-2] [PMID: 28875246]
[31]
Maksymowych, W.P.; Naides, S.J.; Bykerk, V.; Siminovitch, K.A.; van Schaardenburg, D.; Boers, M.; Landewé, R.; van der Heijde, D.; Tak, P.P.; Genovese, M.C.; Weinblatt, M.E.; Keystone, E.C.; Zhukov, O.S.; Abolhosn, R.W.; Popov, J.M.; Britsemmer, K.; van Kuijk, A.W.; Marotta, A. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J. Rheumatol., 2014, 41(11), 2104-2113.
[http://dx.doi.org/10.3899/jrheum.131446] [PMID: 25128504]
[32]
Carrier, N.; Marotta, A.; de Brum-Fernandes, A.J.; Liang, P.; Masetto, A.; Ménard, H.A.; Maksymowych, W.P.; Boire, G. Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis. Arthritis Res. Ther., 2016, 18(1), 37.
[http://dx.doi.org/10.1186/s13075-016-0935-z] [PMID: 26832367]
[33]
Qu, C.H.; Hou, Y.; Bi, Y.F.; Han, Q.R.; Jiao, C.H.; Zou, Q.F. Diagnostic values of serum IL-10 and IL-17 in rheumatoid arthritis and their correlation with serum 14-3-3η protein. Eur. Rev. Med. Pharmacol. Sci., 2019, 23(5), 1899-1906.
[PMID: 30915732]
[34]
Maksymowych, W.P.; Boire, G.; van Schaardenburg, D.; Wichuk, S.; Turk, S.; Boers, M.; Siminovitch, K.A.; Bykerk, V.; Keystone, E.; Tak, P.P.; van Kuijk, A.W.; Landewé, R.; van der Heijde, D.; Murphy, M.; Marotta, A. 14-3-3η autoantibodies: diagnostic use in early rheumatoid arthritis. J. Rheumatol., 2015, 42(9), 1587-1594.
[http://dx.doi.org/10.3899/jrheum.141385] [PMID: 26178283]
[35]
Hirata, S.; Marotta, A.; Gui, Y.; Hanami, K.; Tanaka, Y. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res. Ther., 2015, 17(1), 280.
[http://dx.doi.org/10.1186/s13075-015-0799-7] [PMID: 26449724]
[36]
Kor, A.; Yalçın, M.; Erten, Ş.; Maraş, Y.; Oğuz, E.F.; Doğan, İ.; Atalar, E.; Başer, S.; Erel, Ö. 14-3-3η proteins as a diagnostic marker, disease activation indicator, and lymphoma predictor in patients with primary sjögren syndrome. Arch. Iran Med., 2023, 26(10), 582-591.
[http://dx.doi.org/10.34172/aim.2023.85] [PMID: 38310415]